Sign up
Log in
Why Sarepta Therapeutics Stock Is Rising Today
Share
Listen to the news

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stock is trading higher on Thursday after it was announced the company will be added to the S&P MidCap 400.

What Happened: Effective prior to the opening of trading on June 3, Sarepta Therapeutics will join the S&P MidCap 400, replacing Shockwave Medical (NASDAQ:SWAV).

Johnson & Johnson (NYSE:JNJ) is expected to acquire Shockwave Medical in a deal that is currently pending final closing conditions. Johnson and Johnson is an S&P 500 constituent.

Related Link: Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session

How To Buy Sarepta Therapeutics Shares

Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.

For example, in Sarepta Therapeutics’ case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

SRPT Price Action: Sarepta Therapeutics shares were up 6.67% at $123.99 at the time of publication, according to data from Benzinga Pro.

Image: Courtesy of Sarepta Therapeutics, Inc.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.